Evidence map›Paper›PMID 36684809›Full record

ReviewJournal of translational autoimmunity2023

PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales.

Francesca Colapietro, M Eric Gershwin, Ana Lleo

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of translational autoimmunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.Journal of gastroenterology and hepatology · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. A Review of Therapies for Primary Biliary Cholangitis.Gastroenterology & hepatology · 2026
    Article
  9. Review
  10. Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Review
  11. Review
  12. New therapies for primary biliary cholangitis.Hepatology international · 2026
    Review
  13. Review
  14. Review
  15. Lipidome remodeling in primary biliary cholangitis.Lipids in health and disease · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Francesca ColapietroDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
M Eric GershwinDivision of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, CA, USA.
Ana LleoDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Humanitas University · ITUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Primary biliary cholangitis (PBC) is an autoimmune liver disease involving the small intrahepatic bile ducts; when untreated or undertreated, it may evolve to liver fibrosis and cirrhosis. Ursodeoxycholic Acid (UDCA) is the standard of care treatment, Obeticholic Acid (OCA) has been approved as second-line therapy for those non responder or intolerant to UDCA. However, due to moderate rate of UDCA-non responders and to warnings recently issued against OCA use in patients with cirrhosis, further therapies are needed.Areas covered. Deep investigations into the pathogenesis of PBC is leading to proposal of new therapeutic agents, among which peroxisome proliferator-activated receptor (PPAR) ligands seem to be highly promising given the preliminary, positive results in Phase 2 and 3 trials. Bezafibrate, the most evaluated, is currently used in clinical practice in combination with UDCA in referral centers. We herein describe completed and ongoing trials involving PPAR agonists use in PBC, analyzing pits and falls. Expert opinion: Testing new therapeutic opportunities in PBC is challenging due to its low prevalence and slow progression. However, new drugs including PPAR agonists, are currently under investigation and should be considered for at-risk PBC patients.

Indexed as

AEs, adverse eventsAIH, Autoimmune HepatitisALP, Alkaline PhosphataseAMA, Antimitochondrial antibodiesBZF, BezafibrateCKD, chronic kidney diseaseElafibranorFDA, Food and DrugFF, FenofibrateFibratesFXR, Farnesoid X ReceptorGGT, γ-glutamil transferaseHCC, Hepatocellular CarcinomaHDL, high-density lipoproteinHR, Hazard RatioHSC, Hepatic Stellate CellsIgM, Immunoglobulin MIL-1β, Interleukin-1LDL, low-density- lipoproteinLT, Liver TransplantMDR3, multidrug resistance protein 3NASH, Non Alcoholic Steato-HepatitsNRS, Numerical Raing ScaleOCA, Obeticholic AcidOR, Odds RatioPAR, protease-activated receptorsPBC, Primary Biliary CholangitisPC, phosphatidylcholinePH, Portal HypertensionPPAR agonistsPPAR, peroxisome proliferator-activated receptorPrimary biliary cholangitisQoL, Quality of LifeRCT, randomized controlled trialSAE, Severe Adverse EventSaroglitazarSeladelparTGR, transmembrane G protein-coupled receptorTLR, Toll Like ReceptorTNF-α, Tumor Necrosis Factor- αUDCAUDCA, ursodeoxycholic acidUK, United KingdomULN, upper limit of normalVAS, Visual Analogue ScaleVRS, Verbal Rating Scale

Identifiers

PMID36684809
PMCPMC9850184
OpenAlexW4313537568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.